Afternoon Update: Key Details To Know About NYSE American Profile (ATNM)
There's no way around it. It's a bloodbath out there today.
The Dow... The Nasdaq... The NYSE...
Everywhere you look, it's red. But here's why that shouldn't stop you from keeping ATNM high on your watch-list near term.
The company is coming off incredible news over the weekend. Check it out here: Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
Plus, Barchart continues to report a multitude (over 10) triggered technicals across the short, medium, and long term.
Don't forget what we found over at MarketBeat. Multiple analyst targets (including one from HC Wainwright of $53) provide ATNM with a ton of potential upside from current trading levels.
Long story short, even though we're swimming in a sea of red today, ATNM needs to continue to be researched moving forward.
If there are any more updates, I'll have them out to you quickly.
Back on radar, here's a past champ profile riding a red hot chart in 2023.
When I brought this profile to your attention back in 2022, it absolutely erupted.
During its chart-shattering, vertical surge, it became a multi-dollar mover in just a handful of days.
Its approximate 40+% move showed how explosive this breakout idea can be in a short amount of time.
But now it's 2023. And it's time to get it back on radar again.
Over the weekend, the company made a huge announcement in regards to "positive results" that could become a game-changing catalyst going into Tuesday's opening bell.
On top of that, Barchart is reporting 10+ bullish technical indicators across the short, medium, and long term.
And with it trading above 3 key potential lines of support, having a float of fewer than 25Mn shares, and having a $53 analyst target, this past champ needs immediate attention.
For Tuesday, February 21st, there is only one profile NYSE American breakout idea to have at the top of your watch-list:
*Actinium Pharmaceuticals, Inc. (ATNM)*
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs.
And ATNM has multiple potential catalysts to pay attention to right now. Check them out:
No. 1 - Could Saturday's "Positive Results" Announcement Fuel ATNM To A Near Term Breakout?
No. 2 - Bullish Triggered Technicals Galore
No. 3 - ATNM Has Strong Analyst Coverage Including A Massive HC Wainwright $53 Target
No. 4 - New Partnership With The NCI Could Prove Extremely Fruitful Long Term
No. 5 - Low Float Volatility Possible On Daily Basis
But more on those in a second...
There is Demand For a Leukemia Cure... and the Market Looks Lucrative
The leukemia therapeutics market could reach $17.1Bn by 2024 from $12.3Bn in 2019, at a CAGR of 6.8%.